Trials / Completed
CompletedNCT05355467
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Mylan (Taiwan) Ltd · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir disoproxil fumarate | Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks. |
| OTHER | Historical Data | Historical Data |
Timeline
- Start date
- 2019-08-21
- Primary completion
- 2021-07-13
- Completion
- 2021-07-13
- First posted
- 2022-05-02
- Last updated
- 2022-05-02
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05355467. Inclusion in this directory is not an endorsement.